Study Design and Participants
cancer treatment(s
MALIGNANT NEOPLASM, MAY
This was a multicenter, sham-controlled, randomized clinical trial performed between May 1, 2019, and December 11, 2021, at 6 hospitals across China. The trial protocol (Patients 18 to 85 years of age were screened for the following (must have all for inclusion): diagnosis of histologically confirmed malignant neoplasm, receiving stable cancer treatment(s), life expectancy of 6 months or longer, and receiving an opioid regimen with a total daily dose of 30 to 1000 mg of oral morphine equivalent for at least 2 weeks. Patients were included in the trial if they had received a diagnosis of OIC according to the Rome IV criteria,